Till startsida
University of Gothenburg
To content Read more about how we use cookies on gu.se

Group Jan-Erik Damber

Research summary

We focus on the behavior of castration-resistant prostate cancer (CRPC) with the aim to identify new therapeutic targets. We also investigate the direct role of androgen deprivation therapy (ADT) in the differentiation of the highly metastatic phenotype associated with CRPC.

Prostate cancer is initially dependent on circulating androgens, and therefore ADT is the standard treatment for advanced disease. The effect is often good, but tumors inevitably relapse in a CRPC form, which is often fatal. CRPC often still expresses androgen receptor (AR) and mechanisms for its ability to grow in castrate testosterone levels includes increased AR expression or sensitivity together with an acquired capacity of de novo steroid synthesis or conversion of steroid precursors to support AR with sufficient ligand for transcriptional activation.

Normally, testosterone induces prostate epithelial cell differentiation and regulates prostate vasculature. We and others have shown that ADT induces de-differentiation not only in androgen-dependent cells, but also in CRPC cells. Several pro-metastatic proteins are induced by ADT. The nature of these changes and their dependence on intratumoral androgens, possible environmental specificity, role in metastasis and drug resistance, and potential as future drug targets, are all subjects for experimental projects in our group.

In a more clinically related part of our research we study the effect of ADT on anti-angiogenic cytotoxic treatment strategies in animal models. We also develop alpha-radio immunotherapy specifically for bone metastasis of prostate cancer in collaboration with Drs. Jacobsson and Bäck at the department of Radiation Physics.

Research tools and resources

We use molecular and cellular techniques to study ADT-induced changes in both in vitro and in vivo systems including mouse xenograft models of human prostate cancer. Further, we collect human samples from different stages in disease progression for molecular analysis.

Current group members

Jan-Erik Damber, MD, PhD, Professor
Andreas Josefsson, MD, PhD
Karin Welén, PhD
Neha Singh, PhD
Delila Gasi Tandefelt, PhD, Researcher
Daniel Åhs, PhD student
Junchi Huang, PhD student
Åsa Jellvert, MD, PhD student
Karin Larsson, PhD
Emelie Tubbin, Lab Assistant

Recent publications

  1. Welén K, Jennbacken K, Tešan T, Damber JE. Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts. Prostate Cancer Prostatic Dis. 2009; 12(1), 41–46.
  2. Jennbacken K, Gustavsson H, Horn M, Vallbo C, Welén K, Damber JE. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts - an effect influenced by testosterone. Prostate, 2009, 69(11):1164–1175.
  3. Gustavsson H, Wang W, Jennbacken K, Welén K, Damber JE. ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer. BJU Int. 2009; 104(11):1786–1790.
  4. Jennbacken K, Tešan T, Wang W, Gustavsson H, Damber JE, Welén K. N-cadherin increased after androgen deprivation and is associated with metastasis in prostate cancer. Endocr Relat Cancer. 2010, 17(2):469–479.
  5. Gustavsson H, Tešan T, Jennbacken K, Kuno K, Damber JE, Welén K. ADAMTS1 is involved in the regulation of blood vessel morphology, TSP1 levels and tumor growth in experimental prostate cancer. BMC Cancer. 2010 Jun 14, 10:288


More group Damber publications on PubMed

Contact information

Jan-Erik Damber

E-mail: Jan-Erik Damber
Phone: +46 (0)31 342 9020

Visiting address:
Sahlgrenska University Hospital
Bruna Stråket 11B
413 45 Gothenburg

Page Manager: Yael Zukovsky Fitoussi|Last update: 10/9/2019

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?